Listing, initial funding and Norwegian exploration
The group listed in August 2021; share issues and a loan drove the six-month financing inflow rather than operating generation.
Kuniko’s five reported periods remain an exploration-stage financial history: equity and exploration carrying value expanded through FY2023, cash fell sharply in FY2024 without a financing inflow, and FY2025 funding restored cash while current borrowings, negative working capital and a going-concern material uncertainty became central to the balance-sheet reading.
Reading the figures: Units are stated above each table or beside the metric. Brackets denote negative amounts. Supported nil is shown as zero; unlike reporting bases remain separately labelled.
Consolidated closing cash at 31 December 2025.
A$0.650m unsecured loan plus A$0.500m overdraft facility.
Issuer-reported negative net working capital and going-concern material uncertainty.
Loss after income tax, not an adjusted measure.
This review covers FY2021–FY2025 annual extraction records. FY2021 is a six-month period ended 31 December 2021; later income and cash-flow columns cover 12 months. The principal view is consolidated Group financial statements, not the parent-only historical comparatives also present in the packet.
Kuniko remained an exploration business. FY2025 describes one exploration industry assessed at company level across Norway, Canada and Australia, so none of the financial measures here is presented as production revenue, resource economics or a valuation.
The group listed in August 2021; share issues and a loan drove the six-month financing inflow rather than operating generation.
The Skuterud programme expanded to 11 holes and 3,240 metres after visible cobalt minerals were identified; exploration payments were A$4.723m.
Closing cash was A$6.742m and financing cash inflow A$7.781m while the statutory loss was A$5.136m.
On 8 February 2024 the company terminated James Bay lithium options with no further cash or share payments expected. Ertelien’s maiden resource was defined in April and updated in December; Gulvag was fully impaired and Undal Nyberget partially impaired.
The September–October entitlement offer and placements raised about A$2.72m before costs; year-end current borrowings were A$1.150m. Undal Nyberget capitalised expenditure was fully impaired after licence expiration and a one-year reapplication ineligibility.
FY2025 cash recovery was accompanied by financing inflow, but the issuer also identified negative net working capital and a material going-concern uncertainty. The balance-sheet table provides the period-by-period amounts.
The exploration carrying amount reached A$12.360m at FY2025 and represented most total assets. It differs from investing cash use and from mineral-resource information.
A$ million
AI-generated presentation · values from Consolidated financial position — closing balances (A$ million); no missing values plotted as zero.
A$ million
AI-generated presentation · values from Consolidated financial position — closing balances (A$ million); no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 5.768 | 6.646 | 6.742 | 0.929 | 1.437 |
| Exploration and evaluation carrying amount | 1.429 | 4.714 | 8.955 | 11.217 | 12.360 |
| Total assets | 7.739 | 12.516 | 16.851 | 12.649 | 13.967 |
| Total liabilities | 1.052 | 0.450 | 0.624 | 1.005 | 1.951 |
| Total equity | 6.687 | 12.066 | 16.226 | 11.644 | 12.016 |
Consolidated closing balances at 31 December. FY2021 is a six-month income/cash-flow period but a 31 December balance date.
All amounts are A$ million, calculated as reported dollar values ÷ 1,000,000. Saved annual-extraction claims identify AUD across FY2021–FY2025.
Exploration and evaluation is a carrying amount, not exploration cash spend, resource value or mine valuation.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Kuniko reported a statutory loss after tax in every displayed period. FY2025 was smaller than FY2024, but this remains a statutory-loss series, distinct from cash use and any adjusted earnings measure.
The comparable cost extracts show elevated share-based payments in FY2021 and FY2023 and the largest impairment magnitude in FY2024. Expense magnitudes are explicitly calculated from signed expense records.
A$ million
AI-generated presentation · values from Statutory loss after tax (A$ million); no missing values plotted as zero.
A$ million
AI-generated presentation · values from Selected statutory cost drivers — expense magnitudes (A$ million); no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Loss after income tax | (2.039) | (2.727) | (5.136) | (4.693) | (3.220) |
Signed statutory consolidated losses after tax. FY2021 covers six months. A separate FY2023 extraction record differs slightly; the primary-statement value is used.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Administrative expenses | 0.249 | 0.530 | 0.933 | 0.874 |
| Consulting and legal fees | 0.186 | 0.346 | 0.681 | 0.435 |
| Employee benefit expense | 0.267 | 0.507 | 0.747 | 0.879 |
| Share-based payments expense | 0.904 | 0.258 | 1.331 | 0.295 |
| Impairment expense | 0.303 | 0.643 | 0.049 | 2.048 |
Expenses are presented as positive magnitudes. FY2021 covers six months; the other columns cover twelve months.
FY2025 does not have a complete comparable cost breakdown in the saved extractions.
FY2023 administrative expense uses the original A$932,973. The following report presents A$946,250 as its comparative; that difference is not reconciled by the saved records.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Operating cash was used throughout the period. Exploration payments are a major investing component, but the report preserves the full investing subtotal where other investing lines were reported.
Financing supported the earlier expansion, was explicitly nil in FY2024, and resumed in FY2025. Gross share-issue cash proceeds and the separate entitlement/placement claim use different stated bases and are not forcibly reconciled.
A$ million
AI-generated presentation · values from Consolidated cash-flow lanes (A$ million); no missing values plotted as zero.
A$ million
AI-generated presentation · values from Consolidated cash-flow lanes (A$ million); no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Net cash used in operating activities | (0.827) | (1.806) | (3.000) | (2.081) | (1.993) |
| Net cash used in investing activities | (1.453) | (4.759) | (4.622) | (3.701) | (0.516) |
| Payments for exploration and evaluation | (1.448) | (4.723) | (4.597) | (3.696) | (0.516) |
| Net cash from financing activities | 8.032 | 7.532 | 7.781 | 0.000 | 3.015 |
Negative values are cash used. FY2024 financing is an issuer-reported dash/nil source value, displayed as 0.000 only because nil is explicit.
Investing cash flow is not replaced by exploration payments: other investing lines occur in FY2021–FY2024. FY2021 is not annualised.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
The February 2025 unsecured facility had A$0.556m principal and A$0.490m net proceeds. It was closed before the 30 July replacement facility, so the A$0.650m replacement at 20% should not be grossed up with the earlier facility as concurrent debt. The A$1.150m year-end total also includes the A$0.500m overdraft.
After balance date, the issuer secured firm commitments for a A$3.75m placement in two tranches, the second subject to shareholder approval. Given internally inconsistent source wording around completion and share count, this review treats it as a qualified commitment structure and does not say the full A$3.75m completed.
The exploration carrying amount increased despite impairment. The roll-forward distinguishes additions from impairment and retains an unlabelled movement without assigning it to acquisition, foreign exchange or another unsupported cause.
The issuer says Undal Nyberget was fully impaired due to licence expiration and a one-year reapplication ineligibility. This is an accounting/project event, not a forecast or resource valuation.
A$ million
| Metric | FY2025 |
|---|---|
| Opening carrying amount | 11.217 |
| Additions through expenditure | 0.765 |
| Impairment expense | (0.306) |
| Unlabelled movement | 0.684 |
| Closing carrying amount | 12.360 |
The source does not label the A$0.684m movement further; it is retained without assigning an invented meaning. FY2024’s A$0.062m FX movement does not establish the FY2025 movement’s meaning.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Prepared solely from the existing year-by-year extraction datasets. No raw annual-report body, PDF, new database lookup or financial web research was used. Review is against those stored extractions, not a new independent original-document audit.
The source references in this report identify the public disclosures used and should be read with the associated section, table and reporting-period qualifications. This report paraphrases, organises and compares those disclosures for descriptive and educational purposes rather than reproducing source text.
Copyright and other rights in linked reports, company names, logos and third-party materials remain with their respective owners. MII Research does not claim affiliation with or endorsement by the company covered in this report, the ASX or cited organisations.
This report uses AI actively and extensively for evidence extraction, comparison, organisation, calculation checks, drafting, translation planning and presentation. Material claims received reasonable editorial review against cited public sources; this was not an audit, assurance engagement or independent verification. Limitations in public sources, AI systems and review may leave errors, omissions, inconsistencies or translation, classification and interpretation errors.
Any AI-generated visual accompanying this report must carry an adjacent, visible AI-generated label or caption. Such visuals are illustrative rather than source evidence and do not replace the cited annual-report text, table or section source.
This record is for general descriptive and educational information only. It is not financial-product, investment, legal, tax, technical or other professional advice; it is not a securities recommendation, valuation, target price, offer, solicitation or invitation to buy, sell or hold.
It does not consider any reader’s objectives, financial situation, needs, knowledge, experience or risk tolerance. Independently verify material information against the primary disclosures, obtain appropriate independent professional advice and do not use this record as the sole or primary basis for any decision.
Public sources are used in good faith, but no representation or warranty is made as to accuracy, completeness, reliability, currency or fitness for a particular purpose. To the maximum extent permitted by law, MII Research disclaims liability for direct, indirect, incidental, consequential, opportunity or investment loss arising from use of or reliance on this record; nothing excludes or limits liability that cannot lawfully be excluded or limited.
Report suspected errors to MII Research with the relevant report section and primary-source document and page reference so that the record can be reviewed and corrected where appropriate.